mRNA ‐laden lipid nanoparticle‐enabled humanized CD19 CAR ‐T‐cell engineering for the eradication of leukaemic cells
British Journal of Haematology · 2025-02 · 206 (2) · 628-643
DOI: 10.1111/bjh.19988 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 06.01.2025. Verfasst von Zhaozhao Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Nanoparticles, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, RNA, Messenger. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Chimeric antigen receptor T‐cell (CAR‐T) therapy has shown transformative potential in treating malignant tumours, with increasing global approval of CAR‐T products. However, high‐production costs and risks associated with viral vector‐based CAR‐T cells—such as insertional mutagenesis and secondary tumour formation—remain challenges. Our study introduces an innovative CAR‐T engineering approach using mRNA delivered via lipid nanoparticles (LNPs), aiming to reduce costs and enhance safety while maintaining strong anti‐tumour efficacy. We developed an LNP‐based transfection protocol for efficient delivery of mRNA encoding full‐human CAR constructs, achieving high CAR expression and significant cytotoxicity against leukaemic cells in vitro. Co‐culture with Raji cells showed increased cytokine secretion and tumour cell killing by mRNA‐LNP CAR‐T cells. Therapeutic efficacy was further demonstrated in an NOD‐scid‐IL2Rγnull (NSG) mouse model with Raji engraftment, where treated mice exhibited marked tumour regression and extended survival. These findings underscore the potential of mRNA‐LNPs as a non‐viral, effective CAR‐T engineering platform, offering a promising alternative to traditional methods that could improve CAR‐T safety, efficacy and accessibility in clinical cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China.
- Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Chen, Z., Ren, A., Li, Y., Shu, J., Wu, J., Huang, H., Wang, J., Hu, Y., & Mei, H. (2025). mRNA ‐laden lipid nanoparticle‐enabled humanized CD19 CAR ‐T‐cell engineering for the eradication of leukaemic cells. British Journal of Haematology, 206(2), 628-643. https://doi.org/10.1111/bjh.19988
Vancouver
Chen Z, Ren A, Li Y, Shu J, Wu J, Huang H, et al. mRNA ‐laden lipid nanoparticle‐enabled humanized CD19 CAR ‐T‐cell engineering for the eradication of leukaemic cells. British Journal of Haematology. 2025;206(2):628-643. doi:10.1111/bjh.19988
BibTeX
@article{Chen2025,
author = {Chen, Zhaozhao and Ren, Anqi and Li, Yingying and Shu, Jinhui and Wu, Jianghua and Huang, Hekuan and Wang, Jingming and Hu, Yu and Mei, Heng},
title = {mRNA ‐laden lipid nanoparticle‐enabled humanized CD19 CAR ‐T‐cell engineering for the eradication of leukaemic cells},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {2},
pages = {628--643},
doi = {10.1111/bjh.19988}
}
EUVIMED